{"entity":{"id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","aka":["TACTIC-3"],"tldr":"A phase 1/2 trial of TAC01-CLDN18.2 in advanced solid tumours, run by Triumvira Immunologics, Inc., active and no longer recruiting.","summary":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) is a phase 1/2 interventional study registered as NCT05862324 by Triumvira Immunologics, Inc., with 113 participants enrolled, started 2023-08-23 and due to reach its primary completion in 2027-08-01. Interventions recorded: TAC01-CLDN18.2.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05862324","url":"https://clinicaltrials.gov/study/NCT05862324"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["tcr-t"],"targets":[],"drugs":["tac01-cldn18-2"],"companies":["triumvira-immunologics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05862324","phase":"1/2","setting":"A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors","sponsor":"Triumvira Immunologics, Inc.","started":"2023-08-23","startedType":"actual","enrolled":113,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05862324/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"drug":[{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/"}],"company":[{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","route":"/companies/triumvira-immunologics/"}]}}